<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02353780</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY19040127</org_study_id>
    <nct_id>NCT02353780</nct_id>
  </id_info>
  <brief_title>Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept</brief_title>
  <acronym>MAZERATI</acronym>
  <official_title>Mechanistic Studies of B- and T-Cell Function in Rheumatoid Arthritis Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Larry W. Moreland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Agency for Healthcare Research and Quality executive summary indicated that better&#xD;
      comparative effectiveness trial designs are needed to determine the relative merits of&#xD;
      existing versus new and expensive biologic drug therapies for rheumatoid arthritis (RA).&#xD;
      There are now 9 biologic therapies approved for treating RA. Four classes of biologics (TNF&#xD;
      antagonists, B-cell inhibitors, T-cell co-stimulator blocker, and Interleukin-6 receptor&#xD;
      blocker) are approved for use in RA patients with moderate or severe disease activity.&#xD;
      Several critical questions have arisen, such as 1) what therapy should be prescribed after&#xD;
      failure of methotrexate and/or other oral disease modifying antirheumatic drugs (DMARDs) to&#xD;
      adequately control disease activity; 2) what is the level of efficacy of the various biologic&#xD;
      therapies when compared in head-to-head trials; and 3) what are the mechanisms associated&#xD;
      with failure of methotrexate and/or other oral DMARD therapy and responsiveness to biologic&#xD;
      therapies. The MAZERATI study will provide the foundation for answering these questions and&#xD;
      determining the mechanisms associated with these biologic therapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single center, randomized, assessor-blinded, observational longitudinal assessment. Subjects&#xD;
      will be randomized to treatment with an anti-TNF therapy, tocilizumab or abatacept and&#xD;
      evaluated at baseline, and after 1, 3 and 6 months of therapy. All biologics will be&#xD;
      administered subcutaneously (SQ). A blinded assessor will perform clinical disease activity&#xD;
      assessments and blood samples will be obtained for mechanistic studies.&#xD;
&#xD;
      After randomization, patients must take at least one dose of the assigned medication and must&#xD;
      maintain their baseline prednisone and oral disease modifying anti-rheumatic drug (DMARD)&#xD;
      medications until they have received their first dose of assigned medication to be considered&#xD;
      per protocol participants. During the first 3 months of therapy, patients and their&#xD;
      physicians will be permitted to taper but not increase corticosteroids. Adjustments of study&#xD;
      medication or oral DMARDs will not be permitted during the first 3 months of the study except&#xD;
      as outlined in the protocol. Adjustments or additions of analgesics will be permitted&#xD;
      throughout the study period.&#xD;
&#xD;
      Following randomization and treatment initiation, study participants will be seen in the&#xD;
      clinic at 1 month (3-5 weeks), 3 months (10-14 weeks), and 6 months (22-30 weeks) after the&#xD;
      initiation of therapy; at each time point, a blinded clinical disease activity assessment&#xD;
      will occur and blood samples will be obtained for mechanistic studies. The occurrence and&#xD;
      severity of unanticipated problems will be recorded continuously throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low enrollment&#xD;
  </why_stopped>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">November 30, 2018</completion_date>
  <primary_completion_date type="Actual">December 30, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mechanistic Comparisons (Changes in Frequencies of Peripheral Blood Immune Cell Subsets Following Institution of a Subcutaneously Administered TNF Antagonist, Tocilizumab or Abatacept.)</measure>
    <time_frame>0 to 3 months</time_frame>
    <description>There will be no primary efficacy endpoints for the study. The primary endpoint of the study will be changes in frequencies of peripheral blood immune cell subsets following institution of a subcutaneously administered TNF antagonist, tocilizumab or abatacept. Flow ctyometry was performed on peripheral blood T cells to determine frequency of Th17/TfH cells based on cell surface markers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy (CDAI)</measure>
    <time_frame>0 to 3 months</time_frame>
    <description>Efficacy of therapy, as measured by number of participants with Clinical Disease Activity Index (CDAI) of less than 2.8 (remission). CDAI is a composite score of RA disease activity based on patient survey (up to 10 points), physician survey (up to 10 points), + number of swollen joints + number of tender joints. 0 = no disease, max score is 60, higher score = more severe disease. Number of patients achieving remission is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (DAS)</measure>
    <time_frame>3 month and 6 month</time_frame>
    <description>Efficacy as measured by DAS remission with a DAS28-CRP &lt; 2.4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR20, 50, and 70 Response</measure>
    <time_frame>3 month and 6 month</time_frame>
    <description>Efficacy as measured by ACR20, 50, and 70 response at 3 months and 6 months versus baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (EULAR)</measure>
    <time_frame>3 month and 6 month</time_frame>
    <description>Efficacy as measured by European League against rheumatism (EULAR) response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>3 month and 6 month</time_frame>
    <description>Adherence to drug regimen over course of clinical study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid Use</measure>
    <time_frame>3 month and 6 month</time_frame>
    <description>Number of patients with steroid doses remaining below 10 mg/day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corticosteroid Use</measure>
    <time_frame>3 month and 6 month</time_frame>
    <description>Average corticosteroid dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DMARD Use</measure>
    <time_frame>3 month and 6 month</time_frame>
    <description>Number of patients without additional oral DMARDs or with a reduction in the number of oral DMARDs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason for Discontinuation of Treatment</measure>
    <time_frame>3 month and 6 month</time_frame>
    <description>Reason for discontinuation of treatment as provided by patient/provider (side effects, lack of efficacy, cost, patient compliance, etc.)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Rheumatoid Arthritis (RA)</condition>
  <arm_group>
    <arm_group_label>Different TNF inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participant will be prescribed any TNF antagonist in this arm. The treating rheumatologist selects the TNF antagonist and the appropriate options for that therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abatacept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participant will be prescribed abatacept in this arm. The treating rheumatologist selects the appropriate options for that therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tocilizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participant will be prescribed tocilizumab. The treating rheumatologist selects the appropriate options for that therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNF Antagonist (enbrel, humire, remicade, cimzia, symponi)</intervention_name>
    <description>TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.</description>
    <arm_group_label>Different TNF inhibitor</arm_group_label>
    <other_name>Enbrel</other_name>
    <other_name>Humira</other_name>
    <other_name>Remicade</other_name>
    <other_name>Cimzia</other_name>
    <other_name>Symponi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <description>Abatacept; SQ; specifics to be determined by the treating rheumatologist.</description>
    <arm_group_label>Abatacept</arm_group_label>
    <other_name>Orencia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab; SQ; specifics determined by the treating rheumatologist.</description>
    <arm_group_label>Tocilizumab</arm_group_label>
    <other_name>Actemra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of RA by a physician as defined by the 1987 and/or 2010 ACR criteria.&#xD;
&#xD;
          -  18 years of age or less than or equal to 64 at the time of diagnosis of RA.&#xD;
&#xD;
          -  RA Disease Activity CDAI &gt; 10&#xD;
&#xD;
          -  If using oral corticosteroids, must have been on stable dose (≤ 10 mg/day) for at&#xD;
             least 2 weeks prior to study drug initiation.&#xD;
&#xD;
          -  PPD negative or if PPD positive documentation of therapy with INH for at least 1 month&#xD;
             prior to study initiation and negative chest x-ray.&#xD;
&#xD;
          -  Must have been treated within the past year with either methotrexate (MTX),&#xD;
             leflunomide (LEF), hydrochloroquine (HCQ) and/or sulfasalazine (SSZ) for ≥ 3 months.&#xD;
&#xD;
          -  Prior or concurrent use of other oral DMARD therapy, including MTX, leflunomide, SSZ,&#xD;
             and HCQ, is permitted. Patients taking oral DMARDs must be on stable doses of DMARDs&#xD;
             for at least 4 weeks prior to study drug initiation. Subjects are not required to be&#xD;
             taking an oral DMARD.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of cyclophosphamide, penicillamine, cyclosporine A, tacrolimus or gold therapy is&#xD;
             not permitted in the 6 months prior to enrollment.&#xD;
&#xD;
          -  Patients who are using or have used other biologic agents or tofacitinib concomitantly&#xD;
             or prior to this study&#xD;
&#xD;
          -  History of active and/or chronic infection such as hepatitis, pneumonia,&#xD;
             pyelonephritis,herpetic infections or chronic skin infections and any active&#xD;
             opportunistic infection, including but not limited to evidence of active&#xD;
             cytomegalovirus, active Pneumocystis carinii, aspergillosis, histoplasmosis or&#xD;
             atypical mycobacterium infection.&#xD;
&#xD;
          -  Active TB or evidence of latent TB (positive PPD skin test or a history of old or&#xD;
             latent TB on chest x-ray) without adequate therapy for TB.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Patients with current signs or symptoms of uncontrolled renal, gastrointestinal,&#xD;
             endocrine, pulmonary, cardiac, neurologic or cerebral disease.&#xD;
&#xD;
          -  Diagnosis of liver disease or elevated hepatic enzymes, as defined by ALT, AST or both&#xD;
             &gt;1.5 x the upper limit of normal (ULN) or total bilirubin &gt; ULN.&#xD;
&#xD;
          -  Any of the following hematologic abnormalities, confirmed by repeat tests:&#xD;
&#xD;
               1. White blood count &lt; 3,000/µL or &gt; 14,000/µL&#xD;
&#xD;
               2. Lymphocyte count &lt;500/µL&#xD;
&#xD;
               3. Platelet count &lt; 100,000/µL&#xD;
&#xD;
               4. Hemoglobin &lt; 8.0 g/dL&#xD;
&#xD;
               5. Neutrophil count &lt; 2,000 cells/µL&#xD;
&#xD;
          -  Major surgery (including joint surgery) within 8 weeks prior to screening or planned&#xD;
             major surgery within 6 months following randomization.&#xD;
&#xD;
          -  Immunization with a live/attenuated vaccine within 2 months prior to baseline or 3&#xD;
             months of last study visit.&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions to human, humanized, or murine&#xD;
             monoclonal antibodies&#xD;
&#xD;
          -  History of other malignancy within 5 years prior to screening, except for&#xD;
             appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or&#xD;
             Stage I uterine cancer&#xD;
&#xD;
          -  Patients with reproductive potential not willing to use an effective method of&#xD;
             contraception&#xD;
&#xD;
          -  History of alcohol, drug or chemical abuse with 1 year prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry W. Moreland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 30, 2013</study_first_submitted>
  <study_first_submitted_qc>February 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2015</study_first_posted>
  <results_first_submitted>September 9, 2020</results_first_submitted>
  <results_first_submitted_qc>September 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 1, 2020</results_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Dr. Larry W. Moreland</investigator_full_name>
    <investigator_title>Chief, Division of Rheumatology and Clinical Immunology</investigator_title>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>TNF inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Tumor Necrosis Factor Inhibitors</mesh_term>
    <mesh_term>Abatacept</mesh_term>
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Certolizumab Pegol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 20, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT02353780/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Out of 10 enrolled subjects, 9 subjects were randomized to one of three arms. One subject withdrew consent prior to being screened/randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Different TNF Inhibitor</title>
          <description>The participant will be prescribed any TNF antagonist in this arm. The treating rheumatologist selects the TNF antagonist and the appropriate options for that therapy.&#xD;
TNF Antagonist (enbrel, humire, remicade, cimzia, symponi): TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.</description>
        </group>
        <group group_id="P2">
          <title>Abatacept</title>
          <description>The participant will be prescribed abatacept in this arm. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Abatacept: Abatacept; SQ; specifics to be determined by the treating rheumatologist.</description>
        </group>
        <group group_id="P3">
          <title>Tocilizumab</title>
          <description>The participant will be prescribed tocilizumab. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Tocilizumab: Tocilizumab; SQ; specifics determined by the treating rheumatologist.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Different TNF Inhibitor</title>
          <description>The participant will be prescribed any TNF antagonist in this arm. The treating rheumatologist selects the TNF antagonist and the appropriate options for that therapy.&#xD;
TNF Antagonist (enbrel, humire, remicade, cimzia, symponi): TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.</description>
        </group>
        <group group_id="B2">
          <title>Abatacept</title>
          <description>The participant will be prescribed abatacept in this arm. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Abatacept: Abatacept; SQ; specifics to be determined by the treating rheumatologist.</description>
        </group>
        <group group_id="B3">
          <title>Tocilizumab</title>
          <description>The participant will be prescribed tocilizumab. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Tocilizumab: Tocilizumab; SQ; specifics determined by the treating rheumatologist.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="3"/>
                    <count group_id="B4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" lower_limit="25" upper_limit="60"/>
                    <measurement group_id="B2" value="51" lower_limit="43" upper_limit="60"/>
                    <measurement group_id="B3" value="52" lower_limit="42" upper_limit="61"/>
                    <measurement group_id="B4" value="49" lower_limit="25" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="3"/>
                    <count group_id="B4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CDAI</title>
          <description>Clinical Disease Activity Index (CDAI) is a composite score of RA disease activity based on patient survey (up to 10 points), physician survey (up to 10 points), + number of swollen joints + number of tender joints. 0 = no disease, max score is 60, higher score = more severe disease.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="3"/>
                    <count group_id="B4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" lower_limit="10.5" upper_limit="30"/>
                    <measurement group_id="B2" value="17.3" lower_limit="6.5" upper_limit="27.5"/>
                    <measurement group_id="B3" value="17.3" lower_limit="14" upper_limit="20"/>
                    <measurement group_id="B4" value="19.2" lower_limit="6.5" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mechanistic Comparisons (Changes in Frequencies of Peripheral Blood Immune Cell Subsets Following Institution of a Subcutaneously Administered TNF Antagonist, Tocilizumab or Abatacept.)</title>
        <description>There will be no primary efficacy endpoints for the study. The primary endpoint of the study will be changes in frequencies of peripheral blood immune cell subsets following institution of a subcutaneously administered TNF antagonist, tocilizumab or abatacept. Flow ctyometry was performed on peripheral blood T cells to determine frequency of Th17/TfH cells based on cell surface markers.</description>
        <time_frame>0 to 3 months</time_frame>
        <population>Patients (total of 5) who provided blood samples at 0 and 3 months and flow cytometry was performed before study discontinuation are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Different TNF Inhibitor</title>
            <description>The participant will be prescribed any TNF antagonist in this arm. The treating rheumatologist selects the TNF antagonist and the appropriate options for that therapy.&#xD;
TNF Antagonist (enbrel, humire, remicade, cimzia, symponi): TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.</description>
          </group>
          <group group_id="O2">
            <title>Abatacept</title>
            <description>The participant will be prescribed abatacept in this arm. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Abatacept: Abatacept; SQ; specifics to be determined by the treating rheumatologist.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab</title>
            <description>The participant will be prescribed tocilizumab. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Tocilizumab: Tocilizumab; SQ; specifics determined by the treating rheumatologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Mechanistic Comparisons (Changes in Frequencies of Peripheral Blood Immune Cell Subsets Following Institution of a Subcutaneously Administered TNF Antagonist, Tocilizumab or Abatacept.)</title>
          <description>There will be no primary efficacy endpoints for the study. The primary endpoint of the study will be changes in frequencies of peripheral blood immune cell subsets following institution of a subcutaneously administered TNF antagonist, tocilizumab or abatacept. Flow ctyometry was performed on peripheral blood T cells to determine frequency of Th17/TfH cells based on cell surface markers.</description>
          <population>Patients (total of 5) who provided blood samples at 0 and 3 months and flow cytometry was performed before study discontinuation are included in the analysis.</population>
          <units>Th17/TfH cell subset % change</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.38" upper_limit="1.46"/>
                    <measurement group_id="O2" value="2.9" lower_limit="2.9" upper_limit="2.9"/>
                    <measurement group_id="O3" value="0.9" lower_limit="0.7" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy (CDAI)</title>
        <description>Efficacy of therapy, as measured by number of participants with Clinical Disease Activity Index (CDAI) of less than 2.8 (remission). CDAI is a composite score of RA disease activity based on patient survey (up to 10 points), physician survey (up to 10 points), + number of swollen joints + number of tender joints. 0 = no disease, max score is 60, higher score = more severe disease. Number of patients achieving remission is reported.</description>
        <time_frame>0 to 3 months</time_frame>
        <population>CDAI change from 0 to 3 months was calculated for the 5 patients who had this data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Different TNF Inhibitor</title>
            <description>The participant will be prescribed any TNF antagonist in this arm. The treating rheumatologist selects the TNF antagonist and the appropriate options for that therapy.&#xD;
TNF Antagonist (enbrel, humire, remicade, cimzia, symponi): TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.</description>
          </group>
          <group group_id="O2">
            <title>Abatacept</title>
            <description>The participant will be prescribed abatacept in this arm. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Abatacept: Abatacept; SQ; specifics to be determined by the treating rheumatologist.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab</title>
            <description>The participant will be prescribed tocilizumab. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Tocilizumab: Tocilizumab; SQ; specifics determined by the treating rheumatologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy (CDAI)</title>
          <description>Efficacy of therapy, as measured by number of participants with Clinical Disease Activity Index (CDAI) of less than 2.8 (remission). CDAI is a composite score of RA disease activity based on patient survey (up to 10 points), physician survey (up to 10 points), + number of swollen joints + number of tender joints. 0 = no disease, max score is 60, higher score = more severe disease. Number of patients achieving remission is reported.</description>
          <population>CDAI change from 0 to 3 months was calculated for the 5 patients who had this data available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy (DAS)</title>
        <description>Efficacy as measured by DAS remission with a DAS28-CRP &lt; 2.4</description>
        <time_frame>3 month and 6 month</time_frame>
        <population>CRP assays were not run as the study was incomplete due to premature termination of study.</population>
        <group_list>
          <group group_id="O1">
            <title>Different TNF Inhibitor</title>
            <description>The participant will be prescribed any TNF antagonist in this arm. The treating rheumatologist selects the TNF antagonist and the appropriate options for that therapy.&#xD;
TNF Antagonist (enbrel, humire, remicade, cimzia, symponi): TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.</description>
          </group>
          <group group_id="O2">
            <title>Abatacept</title>
            <description>The participant will be prescribed abatacept in this arm. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Abatacept: Abatacept; SQ; specifics to be determined by the treating rheumatologist.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab</title>
            <description>The participant will be prescribed tocilizumab. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Tocilizumab: Tocilizumab; SQ; specifics determined by the treating rheumatologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy (DAS)</title>
          <description>Efficacy as measured by DAS remission with a DAS28-CRP &lt; 2.4</description>
          <population>CRP assays were not run as the study was incomplete due to premature termination of study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR20, 50, and 70 Response</title>
        <description>Efficacy as measured by ACR20, 50, and 70 response at 3 months and 6 months versus baseline</description>
        <time_frame>3 month and 6 month</time_frame>
        <population>ACR20, 50, 70 were not calculated since clinical parameter such as CRP were not collected due to premature termination of study.</population>
        <group_list>
          <group group_id="O1">
            <title>Different TNF Inhibitor</title>
            <description>The participant will be prescribed any TNF antagonist in this arm. The treating rheumatologist selects the TNF antagonist and the appropriate options for that therapy.&#xD;
TNF Antagonist (enbrel, humire, remicade, cimzia, symponi): TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.</description>
          </group>
          <group group_id="O2">
            <title>Abatacept</title>
            <description>The participant will be prescribed abatacept in this arm. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Abatacept: Abatacept; SQ; specifics to be determined by the treating rheumatologist.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab</title>
            <description>The participant will be prescribed tocilizumab. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Tocilizumab: Tocilizumab; SQ; specifics determined by the treating rheumatologist.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR20, 50, and 70 Response</title>
          <description>Efficacy as measured by ACR20, 50, and 70 response at 3 months and 6 months versus baseline</description>
          <population>ACR20, 50, 70 were not calculated since clinical parameter such as CRP were not collected due to premature termination of study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy (EULAR)</title>
        <description>Efficacy as measured by European League against rheumatism (EULAR) response</description>
        <time_frame>3 month and 6 month</time_frame>
        <population>This parameter was not calculated as data was incomplete due to premature termination of study</population>
        <group_list>
          <group group_id="O1">
            <title>Different TNF Inhibitor</title>
            <description>The participant will be prescribed any TNF antagonist in this arm. The treating rheumatologist selects the TNF antagonist and the appropriate options for that therapy.&#xD;
TNF Antagonist (enbrel, humire, remicade, cimzia, symponi): TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.</description>
          </group>
          <group group_id="O2">
            <title>Abatacept</title>
            <description>The participant will be prescribed abatacept in this arm. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Abatacept: Abatacept; SQ; specifics to be determined by the treating rheumatologist.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab</title>
            <description>The participant will be prescribed tocilizumab. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Tocilizumab: Tocilizumab; SQ; specifics determined by the treating rheumatologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy (EULAR)</title>
          <description>Efficacy as measured by European League against rheumatism (EULAR) response</description>
          <population>This parameter was not calculated as data was incomplete due to premature termination of study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adherence</title>
        <description>Adherence to drug regimen over course of clinical study</description>
        <time_frame>3 month and 6 month</time_frame>
        <population>Number of patients who adhered to drug treatment through 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Different TNF Inhibitor</title>
            <description>The participant will be prescribed any TNF antagonist in this arm. The treating rheumatologist selects the TNF antagonist and the appropriate options for that therapy.&#xD;
TNF Antagonist (enbrel, humire, remicade, cimzia, symponi): TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.</description>
          </group>
          <group group_id="O2">
            <title>Abatacept</title>
            <description>The participant will be prescribed abatacept in this arm. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Abatacept: Abatacept; SQ; specifics to be determined by the treating rheumatologist.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab</title>
            <description>The participant will be prescribed tocilizumab. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Tocilizumab: Tocilizumab; SQ; specifics determined by the treating rheumatologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence</title>
          <description>Adherence to drug regimen over course of clinical study</description>
          <population>Number of patients who adhered to drug treatment through 6 months.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steroid Use</title>
        <description>Number of patients with steroid doses remaining below 10 mg/day</description>
        <time_frame>3 month and 6 month</time_frame>
        <population>Steroid dose information was not collected at 3 and 6 months as the study was terminated early with insufficient patient enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Different TNF Inhibitor</title>
            <description>The participant will be prescribed any TNF antagonist in this arm. The treating rheumatologist selects the TNF antagonist and the appropriate options for that therapy.&#xD;
TNF Antagonist (enbrel, humire, remicade, cimzia, symponi): TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.</description>
          </group>
          <group group_id="O2">
            <title>Abatacept</title>
            <description>The participant will be prescribed abatacept in this arm. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Abatacept: Abatacept; SQ; specifics to be determined by the treating rheumatologist.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab</title>
            <description>The participant will be prescribed tocilizumab. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Tocilizumab: Tocilizumab; SQ; specifics determined by the treating rheumatologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Steroid Use</title>
          <description>Number of patients with steroid doses remaining below 10 mg/day</description>
          <population>Steroid dose information was not collected at 3 and 6 months as the study was terminated early with insufficient patient enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corticosteroid Use</title>
        <description>Average corticosteroid dose</description>
        <time_frame>3 month and 6 month</time_frame>
        <population>Data not collected due to early termination of study</population>
        <group_list>
          <group group_id="O1">
            <title>Different TNF Inhibitor</title>
            <description>The participant will be prescribed any TNF antagonist in this arm. The treating rheumatologist selects the TNF antagonist and the appropriate options for that therapy.&#xD;
TNF Antagonist (enbrel, humire, remicade, cimzia, symponi): TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.</description>
          </group>
          <group group_id="O2">
            <title>Abatacept</title>
            <description>The participant will be prescribed abatacept in this arm. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Abatacept: Abatacept; SQ; specifics to be determined by the treating rheumatologist.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab</title>
            <description>The participant will be prescribed tocilizumab. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Tocilizumab: Tocilizumab; SQ; specifics determined by the treating rheumatologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Corticosteroid Use</title>
          <description>Average corticosteroid dose</description>
          <population>Data not collected due to early termination of study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DMARD Use</title>
        <description>Number of patients without additional oral DMARDs or with a reduction in the number of oral DMARDs</description>
        <time_frame>3 month and 6 month</time_frame>
        <population>Data was not collected for DMARDs due to premature termination of study due to insufficient patient enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Different TNF Inhibitor</title>
            <description>The participant will be prescribed any TNF antagonist in this arm. The treating rheumatologist selects the TNF antagonist and the appropriate options for that therapy.&#xD;
TNF Antagonist (enbrel, humire, remicade, cimzia, symponi): TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.</description>
          </group>
          <group group_id="O2">
            <title>Abatacept</title>
            <description>The participant will be prescribed abatacept in this arm. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Abatacept: Abatacept; SQ; specifics to be determined by the treating rheumatologist.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab</title>
            <description>The participant will be prescribed tocilizumab. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Tocilizumab: Tocilizumab; SQ; specifics determined by the treating rheumatologist.</description>
          </group>
        </group_list>
        <measure>
          <title>DMARD Use</title>
          <description>Number of patients without additional oral DMARDs or with a reduction in the number of oral DMARDs</description>
          <population>Data was not collected for DMARDs due to premature termination of study due to insufficient patient enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reason for Discontinuation of Treatment</title>
        <description>Reason for discontinuation of treatment as provided by patient/provider (side effects, lack of efficacy, cost, patient compliance, etc.)</description>
        <time_frame>3 month and 6 month</time_frame>
        <population>all 9 patients enrolled and assigned to a study group were analyzed for completion of therapy. All patients completed therapy and none discontinued so no additional data to report.</population>
        <group_list>
          <group group_id="O1">
            <title>Different TNF Inhibitor</title>
            <description>The participant will be prescribed any TNF antagonist in this arm. The treating rheumatologist selects the TNF antagonist and the appropriate options for that therapy.&#xD;
TNF Antagonist (enbrel, humire, remicade, cimzia, symponi): TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.</description>
          </group>
          <group group_id="O2">
            <title>Abatacept</title>
            <description>The participant will be prescribed abatacept in this arm. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Abatacept: Abatacept; SQ; specifics to be determined by the treating rheumatologist.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab</title>
            <description>The participant will be prescribed tocilizumab. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Tocilizumab: Tocilizumab; SQ; specifics determined by the treating rheumatologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Reason for Discontinuation of Treatment</title>
          <description>Reason for discontinuation of treatment as provided by patient/provider (side effects, lack of efficacy, cost, patient compliance, etc.)</description>
          <population>all 9 patients enrolled and assigned to a study group were analyzed for completion of therapy. All patients completed therapy and none discontinued so no additional data to report.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over the course of study participation which was 6 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Different TNF Inhibitor</title>
          <description>The participant will be prescribed any TNF antagonist in this arm. The treating rheumatologist selects the TNF antagonist and the appropriate options for that therapy.&#xD;
TNF Antagonist (enbrel, humire, remicade, cimzia, symponi): TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.</description>
        </group>
        <group group_id="E2">
          <title>Abatacept</title>
          <description>The participant will be prescribed abatacept in this arm. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Abatacept: Abatacept; SQ; specifics to be determined by the treating rheumatologist.</description>
        </group>
        <group group_id="E3">
          <title>Tocilizumab</title>
          <description>The participant will be prescribed tocilizumab. The treating rheumatologist selects the appropriate options for that therapy.&#xD;
Tocilizumab: Tocilizumab; SQ; specifics determined by the treating rheumatologist.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye floaters</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increase in cholesterol levels</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the small number of patients enrolled in each group, it was not possible to perform statistical analyses of the primary endpoints. These are fairly broad measures that require large numbers to identify patterns in subset changes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Larry Moreland, MD</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-648-4098</phone>
      <email>lwm5@pitt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

